Extrait

(1) to assess long-term changes from baseline in total hip bone mineral density (BMD) after 10 years of treatment with odanacatib 50 mg once-weekly in postmenopausal osteoporotic women previously treated with once-weekly odanacatib for at least 5 years (2) to assess safety and tolerability of long-term treatment with odanacatib 50 mg once-weekly.

Critère d'inclusion

• Osteoporosis

Liens

• ictrp
• euctr